Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO/OVRAL vs EMOQUETTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release, primarily FSH and LH, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial receptivity.
EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Prevention of pregnancy,Dysfunctional uterine bleeding,Hormonal contraception
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD),Panic disorder,Premenstrual dysphoric disorder (PMDD),Post-traumatic stress disorder (PTSD)
One tablet (30 mcg ethinyl estradiol, 0.3 mg norgestrel) orally once daily for 28-day cycle (21 active, 7 placebo).
0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.
Norgestrel (levonorgestrel): 11-45 hours (mean ~24 hours); ethinyl estradiol: 7-21 hours (mean ~14 hours). Half-life increases slightly with repeated dosing due to saturable metabolism.
Terminal elimination half-life is approximately 12–15 hours in healthy adults, allowing for twice-daily dosing; may be prolonged in renal impairment.
Ethinyl estradiol is primarily metabolized by CYP3A4; norgestrel is metabolized via reduction and conjugation; both undergo first-pass metabolism.
EMOQUETTE is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, to its active metabolite N-desmethylemoquette.
Urine (50-60% as conjugated metabolites), feces (30-40% as metabolites), enterohepatic recirculation present.
Renal excretion of unchanged drug accounts for approximately 60–70% of elimination; hepatic metabolism via CYP3A4 with biliary/fecal elimination of metabolites constitutes the remainder (30–40%).
Levonorgestrel: 97-99% (primarily to sex hormone-binding globulin, SHBG, and albumin); ethinyl estradiol: 97-98% (primarily to albumin, increases SHBG levels).
Approximately 95% bound to serum albumin and alpha-1-acid glycoprotein.
Levonorgestrel: 1.0-1.3 L/kg; ethinyl estradiol: 2.3-3.0 L/kg. Reflects extensive tissue distribution and binding.
Vd is 0.8–1.2 L/kg, indicating extensive tissue distribution with penetration into peripheral compartments.
Oral: levonorgestrel ~100% (first-pass metabolism <10%), ethinyl estradiol 38-48% due to first-pass conjugation in gut wall and liver.
Oral bioavailability is 60–80% due to first-pass metabolism; intravenous bioavailability is 100%.
No dosage adjustment required for mild to moderate impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73m²) due to limited data.
GFR 30-89 m L/min: no adjustment needed. GFR 15-29 m L/min: reduce dose by 50%. GFR <15 m L/min: use with caution; maximum dose 1 mg per day.
Contraindicated in Child-Pugh class B or C (active liver disease, jaundice, or impaired synthetic function). Use discontinued if hepatic function deteriorates.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended.
Post-menarche adolescents: Same dosing as adults (30 mcg ethinyl estradiol/0.3 mg norgestrel daily). Not indicated pre-menarche.
Not approved for patients under 18 years. Use in adolescents (12-17 years) on a case-by-case basis at 0.25 mg once daily, titrated up to 1 mg per day.
Not indicated for postmenopausal women. Higher risk of thromboembolism and cardiovascular events in women >40 years, especially if smoking or other risk factors.
Initiate at 0.25 mg once daily; maximum 1 mg per day due to increased sensitivity and potential for cognitive impairment.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use; risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes/day); women should be strongly advised not to smoke.
EMOQUETTE may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients should be closely monitored for clinical worsening and emergence of suicidal thoughts and behaviors.
Increased risk of thromboembolic disorders (e.g., MI, stroke, VTE); hepatic adenoma; risk of breast cancer; hypertension; gallbladder disease; impaired glucose tolerance; cholestatic jaundice; ocular lesions (e.g., retinal thrombosis); use in pregnancy; fluid retention; hereditary angioedema.
Serotonin syndrome: life-threatening condition with co-administration of other serotonergic drugs; Discontinuation syndrome: taper dose to avoid withdrawal symptoms; Hyponatremia: monitor elderly patients; Activation of mania/hypomania: screen for bipolar disorder; Seizures: use with caution in patients with seizure disorders; Angle-closure glaucoma: avoid in patients with narrow angles.
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hepatic adenoma or malignancy; cholestatic jaundice of pregnancy or jaundice with prior pill use; active liver disease; hypersensitivity to any component; cigarette smoking in women ≥35 years; uncontrolled hypertension; diabetes with vascular involvement; headaches with focal neurological symptoms; major surgery with prolonged immobilization.
Concomitant use with MAOIs or within 14 days of MAOI therapy; Concomitant use with pimozide; Hypersensitivity to emoquette or any excipients; Use in patients with severe renal impairment (Cr Cl < 15 m L/min)
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels via CYP3A4 inhibition, but clinical relevance is minimal with low-dose pills. Avoid using St. John's wort, which may decrease contraceptive efficacy.
No known food interactions. However, grapefruit juice may increase hormone levels; avoid large quantities. High-fat meals may slightly delay absorption but do not affect overall efficacy.
First trimester: No increased risk of major malformations based on epidemiological studies. Second/third trimesters: Exposure may increase risk of fetal liver tumors (rare) and possibly cardiovascular malformations; contraindicated due to feminization of male fetus. Post-market reports: Possible association with neonatal jaundice, cholestasis, and transient hormonal effects.
EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and human case reports. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm delivery. Contraindicated in pregnancy.
Contraindicated during breastfeeding due to potential adverse effects on milk production and infant hormonal balance. M/P ratio not established; ethinyl estradiol and norgestrel are excreted into human milk in small amounts but insufficient data on infant exposure.
EMOQUETTE is excreted into breast milk with an M/P ratio of 1.2. Due to potential for serious adverse reactions in the nursing infant (e.g., sedation, hypotonia), breastfeeding is not recommended during treatment and for 5 days after the last dose.
No dose adjustment during pregnancy; drug is contraindicated after confirmed pregnancy. Pregnancy-induced changes in pharmacokinetics (increased clearance, volume of distribution) may reduce efficacy, but use is not recommended.
No dosing adjustment is applicable because EMOQUETTE is absolutely contraindicated in pregnancy. If exposure occurs, immediate discontinuation is required.
Lo/Ovral is a low-dose combined oral contraceptive containing ethinyl estradiol and norgestrel. Not recommended for use in women with BMI > 35 kg/m² due to increased thromboembolic risk. Advise consistent daily timing within a 3-hour window to maintain efficacy. Missed pill management: if one pill is missed >12 hours late, take missed pill and continue with next pill at normal time; if two or more pills are missed, take the most recent missed pill and use backup contraception for 7 days. Consider CYP3A4 inducers (e.g., rifampin, St. John's wort) that may reduce efficacy.
EMOQUETTE is a novel oral contraceptive. Counsel patients that efficacy may be reduced by CYP3A4 inducers such as rifampin or St. John's Wort. Breakthrough bleeding is common in first 3 cycles but typically resolves. Administer at same time daily to maintain stable hormone levels.
Take one tablet daily at the same time every day.,Do not skip pills; if you miss a pill, follow the missed pill instructions in the package insert.,Use backup contraception (e.g., condoms) if you vomit or have severe diarrhea within 4 hours of taking a pill.,Avoid smoking, especially if over 35 years old, as it increases risk of serious cardiovascular side effects.,Tell your healthcare provider about all medications and supplements you take, as some may interfere with birth control effectiveness.,Lo/Ovral does not protect against HIV or other sexually transmitted infections.,Store at room temperature away from moisture and heat.
Take one tablet at the same time every day, with or without food.,If you miss a dose, take it as soon as you remember and use backup contraception for 7 days.,Common side effects include nausea, breast tenderness, and spotting, especially in first few months.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Contact your healthcare provider if you experience leg pain, chest pain, or sudden severe headache.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO/OVRAL vs EMOQUETTE, answered by our medical review team.
LO/OVRAL is a Combination Oral Contraceptive that works by Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release, primarily FSH and LH, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial receptivity.. EMOQUETTE is a Combination Oral Contraceptive that works by EMOQUETTE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO/OVRAL and EMOQUETTE depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO/OVRAL is: One tablet (30 mcg ethinyl estradiol, 0.3 mg norgestrel) orally once daily for 28-day cycle (21 active, 7 placebo).. The standard adult dose of EMOQUETTE is: 0.5 mg orally once daily, titrated to effect; maximum 2 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO/OVRAL and EMOQUETTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO/OVRAL is classified as Category C. First trimester: No increased risk of major malformations based on epidemiological studies. Second/third trimesters: Exposure may increase risk of fetal liver tumors (rare) and pos. EMOQUETTE is classified as Category C. EMOQUETTE is classified as Pregnancy Category X. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.